Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.730
+0.020 (1.17%)
At close: Aug 13, 2025, 4:00 PM
1.730
0.00 (0.00%)
After-hours: Aug 13, 2025, 5:31 PM EDT

Immuron Revenue

Immuron had revenue of 3.99M AUD in the half year ending December 31, 2024, with 584.38% growth. This brings the company's revenue in the last twelve months to 6.54M, up 82.90% year-over-year. In the fiscal year ending June 30, 2024, Immuron had annual revenue of 4.90M with 171.67% growth.

Revenue (ttm)
6.54M AUD
Revenue Growth
+82.90%
P/S Ratio
2.93
Revenue / Employee
934,518 AUD
Employees
7
Market Cap
11.87M USD

Revenue Chart

* This company reports financials in AUD.

History

Fiscal Year End Revenue Change Growth
Jun 30, 20244.90M3.10M171.67%
Jun 30, 20231.80M1.04M135.85%
Jun 30, 2022765.19K619.42K424.91%
Jun 30, 2021145.78K-2.37M-94.21%
Jun 30, 20202.52M131.14K5.49%
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro
Jun 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 422.82B
Johnson & Johnson 90.63B
Merck & Co. 63.62B
AbbVie 58.33B
AstraZeneca 56.50B
Novartis AG 55.19B
Eli Lilly and Company 53.26B
Novo Nordisk 49.11B
Revenue Rankings